Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-1558

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 500mg 70518 1558 01

Divalproex Sodium is a medication in a tablet form of 500mg. It is used only with the prescription of the doctor. The tablets are packed in a quantity of 100 HD2. The medication should be kept out of the reach of children, stored at a temperature of 20-26°C (63-77°F); excursions permitted to 15-30°C (59-86°F) [See USP]. The package insert should be followed for the instructions of use. The tablets were repackaged by RemedyRepack Inc., Indiana, PA 15701. The LOT # and Expiry date are not available.*

FDA Label Image

Divalproex Sodium 500mg 70518 1558 02

Divalproex Sodium is a delayed-release medication. The product has an NDC number of 70518-1558-02 and is sourced from Sun Pharma in Cranbury, N.J. The LOT number and expiration date of the product are not provided. The medication should be kept out of the reach of children and stored between 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) as indicated by U.S. Pharmacopeia (USP). The directions for use are provided in the package insert. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium is a medication administered in the form of a 500mg delayed-release tablet. It is RX Only and should be kept out of children's reach. The medication is manufactured by Sun Pharma of Cranbury, N.J. 08512. The medicine should be stored in a dry and cool place, and the instructions to use the drug are to be found in the package insert. The medication has been repackaged by RemedyRepack. The LOT # and expiration date are missing.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

This appears to be a graph with two lines labeled "DVPX" and "Placebo" showing the percentage of patients with an improvement, no change, or worsening, along with a scale ranging from -100% to 100% and a "Reduction in CPS Rate" label. Not enough context is provided to determine what "CPS" refers to or what the two lines represent without additional information.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

The text describes Figure 4 which contains information about the mean 4-week migraine rates for a placebo and a drug called DVPX from Study 1 and Study 2.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.